StockData
FFRNasdaqFinance ServicesFiscal year ends December 31

FF EAI Robotics Ecosystem Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.07−0.09 (-7.76%)

Close on Oct 19, 2026

Market cap
$21.71M
P/E (TTM)
–
Dividend yield
–

About FF EAI Robotics Ecosystem

Finance Services, SIC 6199

AIxCrypto Holdings, Inc. operates within the blockchain, cryptocurrency, and financial technology sectors. The company engages in crypto asset holdings and related investment arrangements, including holding various digital assets such as Bitcoin, Ethereum, Solana, Dogecoin, Ripple, Cardano, and USDTether. Additionally, through historical agreements and transactions, its activities encompass licensing, co-development agreements, and research collaborations, including sponsored research initiatives with academic institutions such as the University of Louisville Research Foundation.

The company maintains its principal executive offices in Carlsbad, California. Its business activities and regulatory compliance efforts cover operations both within the United States and internationally. The provided filing text does not disclose physical store counts or a detailed enumeration of operating facilities.

Summary of the business section of FF EAI Robotics Ecosystem's latest annual report, written by StockData.

Company profile

Company

Legal name
FF EAI Robotics Ecosystem Inc.
Headquarters
El Segundo, CA
Address
1990 E. Grand Avenue 90245
Phone
(760) 918-9165
Employees
10, Dec 31, 2025
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, San Francisco, California

Stock & identifiers

Ticker
FFR
Exchange
Nasdaq
IPO date
Jun 26, 2015
Shares outstanding
20M, Aug 7, 2026
Public float
$5.58M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Nov 14, 2024; 1-for-50 reverse, Nov 5, 2024; 1-for-10 reverse, May 2, 2023; 1-for-10 reverse, Nov 23, 2022; 1-for-6.25 reverse, Aug 14, 2020; 1-for-25 reverse, May 26, 2020; 1-for-10 reverse, May 15, 2018; 1-for-10 reverse, Mar 23, 2018
SEC CIK
1460702
CUSIP
74754R301
ISIN
US74754R3012
LEI
549300D1RXK87UWSJV72
EIN
26-3474527

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jiawei WangCo-Chief Executive Officer1,658
Jason Evan DodierDirector–
Chen ShiDirector–
Graydon BenslerDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024
Michael Poirier
$504.18K$504.18K$46.15K$-5–
FY2023
Michael Poirier
$632.70K$612.87K$514.32K$2–
FY2022
Michael Poirier
$728.45K$262.27K$473.83K$4–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 10 employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 29, 2026Name changeName changed from AIxCrypto Holdings, Inc. to FF EAI Robotics Ecosystem Inc.
Dec 16, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 21, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 19, 2025Name changeName changed from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc.
Oct 7, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 28, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 19, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 1, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2025Late filingNotification of late filing
Oct 22, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 15, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
May 30, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 14, 2024Late filingNotification of late filing
Apr 1, 2024Late filingNotification of late filing
Nov 22, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 26, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 24, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2023Late filingNotification of late filing
Sep 2, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 3, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 29, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 3, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
May 29, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 29, 2020Auditor changeChange in certifying accountant (8-K Item 4.01)
May 20, 2020Name changeName changed from RITTER PHARMACEUTICALS INC to Qualigen Therapeutics, Inc.
Mar 31, 2020Late filingNotification of late filing